CN101506364B - Sdf-1结合性核酸 - Google Patents

Sdf-1结合性核酸 Download PDF

Info

Publication number
CN101506364B
CN101506364B CN2007800305243A CN200780030524A CN101506364B CN 101506364 B CN101506364 B CN 101506364B CN 2007800305243 A CN2007800305243 A CN 2007800305243A CN 200780030524 A CN200780030524 A CN 200780030524A CN 101506364 B CN101506364 B CN 101506364B
Authority
CN
China
Prior art keywords
sdf
nucleic acid
binding
rna
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800305243A
Other languages
English (en)
Chinese (zh)
Other versions
CN101506364A (zh
Inventor
W·普尔斯克
F·雅洛世
D·尤尔伯格
S·克鲁斯曼
K·布赫纳
C·马什
N·丁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Priority to CN201310486348.1A priority Critical patent/CN103555725B/zh
Publication of CN101506364A publication Critical patent/CN101506364A/zh
Application granted granted Critical
Publication of CN101506364B publication Critical patent/CN101506364B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
CN2007800305243A 2006-07-18 2007-07-18 Sdf-1结合性核酸 Active CN101506364B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310486348.1A CN103555725B (zh) 2006-07-18 2007-07-18 Sdf‑1结合性核酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06014957 2006-07-18
EP06014957.2 2006-07-18
PCT/EP2007/006387 WO2008009437A2 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310486348.1A Division CN103555725B (zh) 2006-07-18 2007-07-18 Sdf‑1结合性核酸

Publications (2)

Publication Number Publication Date
CN101506364A CN101506364A (zh) 2009-08-12
CN101506364B true CN101506364B (zh) 2013-10-30

Family

ID=38947372

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800305243A Active CN101506364B (zh) 2006-07-18 2007-07-18 Sdf-1结合性核酸
CN201310486348.1A Active CN103555725B (zh) 2006-07-18 2007-07-18 Sdf‑1结合性核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310486348.1A Active CN103555725B (zh) 2006-07-18 2007-07-18 Sdf‑1结合性核酸

Country Status (16)

Country Link
US (5) US8314223B2 (enExample)
EP (1) EP2041282B1 (enExample)
JP (1) JP5380287B2 (enExample)
KR (2) KR101561652B1 (enExample)
CN (2) CN101506364B (enExample)
AR (1) AR061929A1 (enExample)
AU (1) AU2007276435C1 (enExample)
BR (1) BRPI0714844B8 (enExample)
CA (1) CA2658267C (enExample)
DK (1) DK2041282T3 (enExample)
ES (1) ES2663404T3 (enExample)
MX (1) MX2009000656A (enExample)
PL (1) PL2041282T3 (enExample)
PT (1) PT2041282T (enExample)
RU (1) RU2590709C2 (enExample)
WO (1) WO2008009437A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5380287B2 (ja) 2006-07-18 2014-01-08 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
JP5463621B2 (ja) * 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
SG188220A1 (en) * 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
WO2012055573A1 (en) * 2010-10-29 2012-05-03 Noxxon Pharma Ag Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
EP3233112A2 (en) * 2014-12-17 2017-10-25 Cancer Research Technology Limited Anti-cxcl12 antibody molecules and their uses
WO2017178119A1 (en) * 2016-04-15 2017-10-19 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection
TW202430127A (zh) * 2023-01-19 2024-08-01 國立陽明交通大學 可用於遞送內質網壓力誘導劑或免疫療法的複合奈米粒及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072273B1 (en) * 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
IE920562A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
ATE347695T1 (de) * 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
WO2006058705A1 (de) * 2004-11-29 2006-06-08 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
ES2385924T3 (es) 2006-02-02 2012-08-03 Allergan, Inc. Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
JP5380287B2 (ja) 2006-07-18 2014-01-08 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
EP2100140B1 (en) 2006-11-30 2015-05-06 University Of Virginia Patent Foundation Methods for diagnosing fibrotic lung diseases
PT2190991T (pt) 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072273B1 (en) * 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y. Li et al..Retina-committed Stem Cells Reside in the Bone Marrow and Migrate in vitro to Signals From Damaged Retina.《Invest Ophthalmol Vis Sci》.2005,第46卷第E-Abstract 3247页. *

Also Published As

Publication number Publication date
US20110112172A1 (en) 2011-05-12
AR061929A1 (es) 2008-10-01
US20180163207A1 (en) 2018-06-14
BRPI0714844B1 (pt) 2019-10-01
US8314223B2 (en) 2012-11-20
US9035038B2 (en) 2015-05-19
US20210139909A1 (en) 2021-05-13
PT2041282T (pt) 2018-03-13
MX2009000656A (es) 2009-03-25
CN103555725B (zh) 2017-05-24
PL2041282T3 (pl) 2018-07-31
CN103555725A (zh) 2014-02-05
AU2007276435B2 (en) 2013-01-24
AU2007276435C1 (en) 2013-06-13
KR20130090428A (ko) 2013-08-13
KR101561652B1 (ko) 2015-10-20
HK1131184A1 (en) 2010-01-15
WO2008009437A3 (en) 2008-03-27
BRPI0714844A2 (pt) 2013-11-26
JP2009543567A (ja) 2009-12-10
KR20090039717A (ko) 2009-04-22
DK2041282T3 (en) 2018-04-16
JP5380287B2 (ja) 2014-01-08
CN101506364A (zh) 2009-08-12
AU2007276435A1 (en) 2008-01-24
US20130041019A1 (en) 2013-02-14
CA2658267A1 (en) 2008-01-24
US9822369B2 (en) 2017-11-21
EP2041282A2 (en) 2009-04-01
EP2041282B1 (en) 2018-01-03
CA2658267C (en) 2021-03-30
BRPI0714844B8 (pt) 2023-04-18
US20150232853A1 (en) 2015-08-20
RU2009105494A (ru) 2010-08-27
ES2663404T3 (es) 2018-04-12
RU2590709C2 (ru) 2016-07-10
WO2008009437A2 (en) 2008-01-24
KR101466931B1 (ko) 2014-12-02

Similar Documents

Publication Publication Date Title
CN103555725B (zh) Sdf‑1结合性核酸
CN101796188B (zh) Sdf-1结合核酸及其用途
CN101415825B (zh) 结合mcp-1的核酸
HK1131184B (en) Sdf-i binding nucleic acids
AU2013200034A1 (en) Sdf-i binding nucleic acids
HK1144956B (en) Sdf-1 binding nucleic acids and the use thereof
HK1129127B (en) Mcp-1 binding nucleic acids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131184

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131184

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: Berlin, Germany

Patentee after: TME Pharmaceutical Co.,Ltd.

Address before: Berlin, Germany

Patentee before: NOXXON PHARMA AG

CP01 Change in the name or title of a patent holder